Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. - Test2 - elhamkhani - TriplyDB

Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.

Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.

http://www.wikidata.org/entity/Q51304272

about

Glucagon and heart in type 2 diabetes: new perspectives Carbohydrate-induced secretion of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 Sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors combination therapy in type 2 diabetes: A systematic review of current evidence Sodium-glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin-metformin Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects SGLT2 Inhibitors May Predispose to Ketoacidosis The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure Niclosamide reduces glucagon sensitivity via hepatic PKA inhibition in obese mice: Implications for glucose metabolism improvements in type 2 diabetes Influence of Familial Renal Glycosuria Due to Mutations in the SLC5A2 Gene on Changes in Glucose Tolerance over Time Antidiabetic effects of Brucea javanica seeds in type 2 diabetic rats Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Common variation in the sodium/glucose cotransporter 2 gene SLC5A2 does neither affect fasting nor glucose-suppressed plasma glucagon concentrations.CFTR is involved in the regulation of glucagon secretion in human and rodent alpha cells.Expression and functional assessment of candidate type 2 diabetes susceptibility genes identify four new genes contributing to human insulin secretion.Sodium-glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusions Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus Empagliflozin in the treatment of type 2 diabetes: evidence to date SGLT-2 inhibition and glucagon: Cause for alarm?Mathematical Modeling of Interacting Glucose-Sensing Mechanisms and Electrical Activity Underlying Glucagon-Like Peptide 1 Secretion The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.Possible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, an SGLT2 Inhibitor.Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic Mice Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight.Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males.SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin.Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients.Quality measure attainment with dapagliflozin plus metformin extended-release as initial combination therapy in patients with type 2 diabetes: a post hoc pooled analysis of two clinical studies The renal effects of SGLT2 inhibitors and a mini-review of the literature.The Effect of Tofogliflozin Treatment on Postprandial Glucose and Lipid Metabolism in Japanese Men With Type 2 Diabetes: A Pilot Study.A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans.The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus.Is it time to think about the sodium glucose co-transporter 2 sympathetically?Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition.Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.

P2860

Q26738580-BDA5058A-959E-4C67-A796-8E07328DB899 Q26749211-16AEE481-210D-4566-A316-26A480138911 Q26752703-E42EFE40-26FF-49B7-B42C-75B5BB8515F4 Q26752815-C5E8A5CF-8C09-4E50-AA43-9138CF4588C5 Q28072765-CB84F9A9-F63A-4A52-BD5A-BCB93312E1CC Q28081173-29F4F8EE-0CF5-4D08-9B0D-3E6218602BC6 Q28082343-2DF3A0B7-927D-442A-A565-10FF22AB76A5 Q28359714-568E5B4A-F3FE-4DC8-841B-11734FE99CF3 Q28552106-478DE03C-7CEF-4A78-A326-34F91A7D9207 Q28817360-1D35A0F5-3840-426C-A1BE-08B47E42C785 Q30249371-959A33ED-9C0A-4835-B617-29699135F405 Q33638177-966CA56F-D590-4BD1-8753-56746859EB8E Q33671461-91844E80-6EEE-40AA-B31F-ADA71569C609 Q33726555-ACC7F96E-C6AA-44FC-AA0E-CD71F026D901 Q33820904-7880AA77-4615-43AD-8D8E-BA1A37B48153 Q33871321-40302746-9FB7-4C08-A2BC-3DDBA2B89503 Q34502358-4750DF81-29D8-42BA-AD3E-A3080B108D17 Q35812506-E41892C1-2E02-4BC8-A9CB-92A2B14E5098 Q35858749-5CF82F13-8FEC-4664-91E7-4F8D2A5D9B66 Q35903101-B848CEC9-D2D4-4223-AD1C-2D5F78250836 Q35957448-1FC62D5C-2A17-404A-AADB-765B07A10B62 Q35973246-68FF5864-DC6A-4855-9259-4D5CCBE02C35 Q36001903-BAB74ADE-CA7E-43AE-815E-B705932B2E53 Q36057947-58C5C143-2923-46E3-91AF-318F9704EF9C Q36345951-FFE292C2-7A72-4200-9AD9-AFF7AE3504AE Q36357997-28049C10-278D-4320-BC89-ACE51B0C1C63 Q36435496-07327DC6-6DF6-4303-A5E3-6539B71BA604 Q36716030-63391C9E-1889-4364-B92E-0256FF9FC562 Q36820604-51478AA9-AD4A-4A8F-ABE0-02BBF9D5CFEC Q37055206-257AEBA5-1091-4CDD-A381-A5C90128997B Q37080615-81C370D7-5473-46E2-BEB0-498613184BE2 Q37302700-6D8FC434-BF88-41F2-BDF1-D2C0050B1677 Q37354187-A8C20244-2FFB-4FC2-A9C7-31778A2753E6 Q37632127-1CE7EF98-8C31-4859-9912-448BB653D1DD Q37737187-75C42670-BEF2-43C7-83A3-CCF7AF082CF3 Q38537119-3D19B9E3-B495-42AF-95E9-48C61DF542F8 Q38580783-21FFC878-F916-4889-8B34-F9CCCD2E8723 Q38586588-8ED2592E-C954-453B-8B09-481C64145165 Q38592327-64189EE1-475C-49D0-83B8-225108DED3A0 Q38602771-0E220CEB-84AB-42F5-9B7E-6CD4258565F5

P2860

Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.

http://www.wikidata.org/entity/Q51304272

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Inhibition of the glucose tran ...... s triggers glucagon secretion.

@en

Inhibition of the glucose tran ...... s triggers glucagon secretion.

@nl

type

label

Inhibition of the glucose tran ...... s triggers glucagon secretion.

@en

Inhibition of the glucose tran ...... s triggers glucagon secretion.

@nl

prefLabel

Inhibition of the glucose tran ...... s triggers glucagon secretion.

@en

Inhibition of the glucose tran ...... s triggers glucagon secretion.

@nl

P1433

Q51304272-65B50B7E-8EB2-4295-BAB4-41D57C4BC88F

P1476

Q51304272-ADDF74A4-4DE9-40A8-8A05-197B90CF25F3

P2093

Q51304272-087F1685-46DC-44A1-A28F-DB3D1B233CB1

Q51304272-2227D441-CF5E-4A40-ACED-1DBABD4288EF

Q51304272-2287FA65-EECE-43DE-A0E0-E0C2F2AC66F0

Q51304272-2C3DADD9-68F8-4099-B128-E3AC02119EE5

Q51304272-608AE023-D346-40B9-AE9C-7B6FB99621D1

Q51304272-77EB371A-021D-4F10-AACD-78B6F52E5562

Q51304272-923B2E61-43C9-485C-9B9F-770EABB24B51

Q51304272-C153728B-5718-47EC-BFAD-C72B4B6F52D0

Q51304272-D68D5ED9-F01B-4C7E-87DC-15EF28D6990F

P2860

Q51304272-04D8600F-8CFF-4DBC-83BC-01A0E7F5620A

Q51304272-1104DD13-5F88-479F-9DEE-C5EAC69D3464

Q51304272-1523E200-1545-4D1A-ADDA-70A77478D639

Q51304272-16358547-69B7-4C1D-AE84-E247A644DC1D

Q51304272-24CAB7D3-B826-4A6D-A9A9-E763D51EC260

Q51304272-283E8BB7-2763-4F22-940C-038CCF844583

Q51304272-2C75D1C1-735E-434F-B48D-435A03B3F78C

Q51304272-2D331E78-9FD8-496D-863A-4BAFB8530BCE

Q51304272-307BEED4-C426-4C04-9781-277EA6749F3C

Q51304272-31569F7D-6BE7-40B6-814A-75B339DBC08B

P2888

Q51304272-90D193D3-7759-46E1-B568-8DFCABDDDD0C

P304

Q51304272-4F014F34-E9D0-4099-85B7-73FC7FB0D144

P31

Q51304272-F678F389-AFE3-403D-AFC3-B4A1B085D8F4

P356

Q51304272-97D112FC-C090-4B92-8B30-9FED485E17F0

P407

Q51304272-A4F724D2-0320-4BDA-AB3A-D7E15E9B41CC

P433

Q51304272-8342044E-1DE0-4393-BE99-4B785BE4F3CB

P478

Q51304272-DE8BD99A-3F89-48FE-BA55-18A842B79FE0

P50

Q51304272-27FB92DA-4EDA-4DB6-9637-D42D58F33B00

Q51304272-2A9CD911-F099-47F8-97E6-24DEF4B870FA

Q51304272-481321C9-E04E-43D8-AA95-8A06403EEF1F

Q51304272-7A9A4833-7946-4CE2-AD6C-2A816133E36B

Q51304272-7EE573F4-5A9F-412C-8B4C-E04536645B9E

Q51304272-FD4F2561-250C-4E94-A318-F530E9500DA2

P577

Q51304272-217999C6-7E83-48C3-87F1-4518FA89AED7

P5875

Q51304272-21EA3196-F131-4C05-B3C9-32085D903B7F

P698

Q51304272-8F551318-8A1E-43D8-BB3D-6E300B6C181B

P921

Q51304272-397ada29-bb3f-4889-8a7d-f5f35cc665dd

P356

P1433

Nature Medicine

P1476

Inhibition of the glucose tran ...... ls triggers glucagon secretion

@en

P2093

Abdullah Sener

http://www.w3.org/2001/XMLSchema#string

Cédric Beaucamps

http://www.w3.org/2001/XMLSchema#string

Ericka Moerman

http://www.w3.org/2001/XMLSchema#string

Gurvan Queniat

http://www.w3.org/2001/XMLSchema#string

Iuliana Popescu

http://www.w3.org/2001/XMLSchema#string

Julie Kerr-Conte

http://www.w3.org/2001/XMLSchema#string

Nathalie Delalleau

http://www.w3.org/2001/XMLSchema#string

Valéry Gmyr

http://www.w3.org/2001/XMLSchema#string

Willy J Malaisse

http://www.w3.org/2001/XMLSchema#string

P2860

RETRACTED: Betatrophin: a hormone that controls pancreatic β cell proliferation

The maturity-onset diabetes of the young (MODY1) transcription factor HNF4alpha regulates expression of genes required for glucose transport and metabolism

A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria

Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models

Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.

Evidence based selection of housekeeping genes.

Efficient gene delivery and silencing of mouse and human pancreatic islets

The SLC2 (GLUT) family of membrane transporters.

Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.

Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis.

P2888

P304

512-517

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.3828

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Francois Pattou

Caroline T Bonner

Amar Abderrahmani

Julien Thévenet

P577

2015-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

275216157

http://www.w3.org/2001/XMLSchema#string

P698

25894829

http://www.w3.org/2001/XMLSchema#string

P921